These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28561710)

  • 1. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.
    Henry NL; Bedard PL; DeMichele A
    Am Soc Clin Oncol Educ Book; 2017; 37():106-115. PubMed ID: 28561710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
    El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
    Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX
    Curtit E; Mansi L; Maisonnette-Escot Y; Sautière JL; Pivot X
    Eur J Surg Oncol; 2017 May; 43(5):921-930. PubMed ID: 28087099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
    Chia SKL
    Curr Oncol; 2018 Jun; 25(Suppl 1):S125-S130. PubMed ID: 29910655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-Expression-Based Predictors for Breast Cancer.
    Gupta A; Mutebi M; Bardia A
    Ann Surg Oncol; 2015 Oct; 22(11):3418-32. PubMed ID: 26215189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.
    Havard R; Henry NL
    Future Oncol; 2017 Dec; 13(28):2507-2510. PubMed ID: 29168654
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?
    Markopoulos C; van de Velde C; Zarca D; Ozmen V; Masetti R
    Eur J Surg Oncol; 2017 May; 43(5):909-920. PubMed ID: 27639633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision medicine for metastatic breast cancer--limitations and solutions.
    Arnedos M; Vicier C; Loi S; Lefebvre C; Michiels S; Bonnefoi H; Andre F
    Nat Rev Clin Oncol; 2015 Dec; 12(12):693-704. PubMed ID: 26196250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BREAST CANCER: FROM TARGETED THERAPY TO PRECISION MEDICINE].
    Jerusalem G; Collignon J; Josse C; Schroeder H; Rorive A; Frères P; Lambert F; Koopmansch B; Poncin A; Bours V
    Rev Med Liege; 2015; 70(5-6):269-76. PubMed ID: 26285451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].
    Gonçalves A; Moretta J; Eisinger F; Bertucci F
    Bull Cancer; 2013 Dec; 100(12):1295-310. PubMed ID: 24225763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer.
    Henry NL; Hayes DF
    Oncology (Williston Park); 2007 Oct; 21(11):1301-9; discussion 1311, 1314, 1319. PubMed ID: 18080616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?
    Andre F; Vicier C; Delaloge S
    Am Soc Clin Oncol Educ Book; 2014; ():e5-10. PubMed ID: 24857146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of gene-expression signatures in early stage breast cancer.
    Kwa M; Makris A; Esteva FJ
    Nat Rev Clin Oncol; 2017 Oct; 14(10):595-610. PubMed ID: 28561071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial experience with genomic profiling of heavily pretreated breast cancers.
    Staren ED; Braun D; Tan B; Gupta D; Kim S; Kramer K; Markman M
    Ann Surg Oncol; 2014 Oct; 21(10):3216-22. PubMed ID: 25047475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
    Abu-Khalf M; Pusztai L
    Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden?
    Ribnikar D; Cardoso F
    Am Soc Clin Oncol Educ Book; 2016; 35():e31-8. PubMed ID: 27249737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.
    Muñoz M; Estévez LG; Alvarez I; Fernández Y; Margelí M; Tusquets I; Seguí MA; Lluch A
    Cancer Treat Rev; 2008 Dec; 34(8):701-9. PubMed ID: 18922644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
    Fayanju OM; Park KU; Lucci A
    Ann Surg Oncol; 2018 Feb; 25(2):512-519. PubMed ID: 29159748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.